Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Cytoskeletal transgelin 2 contributes to gender-dependent adipose tissue expandability and immune function.

Ortega FJ, Moreno-Navarrete JM, Mercader JM, Gómez-Serrano M, García-Santos E, Latorre J, Lluch A, Sabater M, Caballano-Infantes E, Guzmán R, Macías-González M, Buxo M, Gironés J, Vilallonga R, Naon D, Botas P, Delgado E, Corella D, Burcelin R, Frühbeck G, Ricart W, Simó R, Castrillon-Rodríguez I, Tinahones FJ, Bosch F, Vidal-Puig A, Malagón MM, Peral B, Zorzano A, Fernández-Real JM.

FASEB J. 2019 Aug;33(8):9656-9671. doi: 10.1096/fj.201900479R. Epub 2019 May 30.

PMID:
31145872
2.

A teaching project on rectal cancer and concentration of procedures: a comparison of oncological results between Catalonia and the rest of autonomous communities.

Codina Cazador A, Biondo S, Espín Basany E, Enríquez Navascues JM, Garcia Granero E, Roig Vila JV, Buxó M.

Rev Esp Enferm Dig. 2019 Jul;111(7):519-529. doi: 10.17235/reed.2019.5901/2018.

3.

Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients.

Cuyàs E, Fernández-Arroyo S, Buxó M, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Morilla I, Stradella A, Viñas G, Cortés J, Verdura S, Brunet J, López-Bonet E, Garcia M, Saidani S, Joven J, Martin-Castillo B, Menendez JA.

Aging (Albany NY). 2019 May 9;11(9):2874-2888. doi: 10.18632/aging.101960.

4.

The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin.

Cuyàs E, Buxó M, Ferri Iglesias MJ, Verdura S, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Morilla I, Stradella A, Viñas G, Cortés J, Joven J, Brunet J, López-Bonet E, Garcia M, Saidani S, Queralt Moles X, Martin-Castillo B, Menendez JA.

Front Oncol. 2019 Mar 28;9:193. doi: 10.3389/fonc.2019.00193. eCollection 2019.

5.

Cause-specific mortality after a breast cancer diagnosis: a cohort study of 10,195 women in Girona and Tarragona.

Ameijide A, Clèries R, Carulla M, Buxó M, Marcos-Gragera R, Martínez JM, Vilardell ML, Vilardell M, Espinàs JA, Borràs JM, Izquierdo Á, Galceran J.

Clin Transl Oncol. 2019 Aug;21(8):1014-1025. doi: 10.1007/s12094-018-02015-5. Epub 2019 Jan 3.

PMID:
30607790
6.

[Excess mortality among breast cancer patients in early stages in Tarragona and Gerona (Spain)].

Clèries R, Ameijide A, Buxó M, Vilardell M, Martínez JM, Marcos-Gragera R, Vilardell ML, Carulla M, Espinàs JA, Galceran J, Borràs JM, Izquierdo Á.

Gac Sanit. 2018 Dec 17. pii: S0213-9111(18)30244-9. doi: 10.1016/j.gaceta.2018.09.008. [Epub ahead of print] Spanish.

7.

A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study.

Martin-Castillo B, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Stradella A, Morilla I, Viñas G, Cortés J, Cuyàs E, Verdura S, Fernández-Ochoa Á, Fernández-Arroyo S, Segura-Carretero A, Joven J, Pérez E, Bosch N, Garcia M, López-Bonet E, Saidani S, Buxó M, Menendez JA.

Oncotarget. 2018 Nov 2;9(86):35687-35704. doi: 10.18632/oncotarget.26286. eCollection 2018 Nov 2.

8.

Decreased TLR3 in Hyperplastic Adipose Tissue, Blood and Inflamed Adipocytes is Related to Metabolic Inflammation.

Latorre J, Moreno-Navarrete JM, Sabater M, Buxo M, Rodriguez-Hermosa JI, Girones J, Fort JM, Vilallonga R, Ricart W, Simo R, Fernandez-Real JM, Ortega FJ.

Cell Physiol Biochem. 2018;51(3):1051-1068. doi: 10.1159/000495487. Epub 2018 Nov 26.

9.

Dosimetric impact of Acuros XB dose-to-water and dose-to-medium reporting modes on VMAT planning for head and neck cancer.

Muñoz-Montplet C, Marruecos J, Buxó M, Jurado-Bruggeman D, Romera-Martínez I, Bueno M, Vilanova JC.

Phys Med. 2018 Nov;55:107-115. doi: 10.1016/j.ejmp.2018.10.024. Epub 2018 Nov 15.

PMID:
30471814
10.

Autoantibodies to cytoplasmic rods and rings in patients with hepatitis C virus infection treated with direct-acting antivirals: The role of prior treatment with interferon plus ribavirin.

Alsius M, Ferri MJ, Buxó M, López C, Serra I, Queralt X, Acero D.

Gastroenterol Hepatol. 2019 Feb;42(2):82-89. doi: 10.1016/j.gastrohep.2018.08.005. Epub 2018 Nov 13. English, Spanish.

PMID:
30446175
11.

Sentinel Amenable Mortality: A New Way to Assess the Quality of Healthcare by Examining Causes of Premature Death for Which Highly Efficacious Medical Interventions Are Available.

Vergara-Duarte M, Borrell C, Pérez G, Martín-Sánchez JC, Clèries R, Buxó M, Martínez-Solanas È, Yasui Y, Muntaner C, Benach J.

Biomed Res Int. 2018 Sep 2;2018:5456074. doi: 10.1155/2018/5456074. eCollection 2018. Review.

12.

Cognitive impairment in early stages of multiple sclerosis is associated with high cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain.

Quintana E, Coll C, Salavedra-Pont J, Muñoz-San Martín M, Robles-Cedeño R, Tomàs-Roig J, Buxó M, Matute-Blanch C, Villar LM, Montalban X, Comabella M, Perkal H, Gich J, Ramió-Torrentà L.

Eur J Neurol. 2018 Sep;25(9):1189-1191. doi: 10.1111/ene.13687. Epub 2018 Jun 22.

PMID:
29797629
13.

Long-term crude probabilities of death among breast cancer patients by age and stage: a population-based survival study in Northeastern Spain (Girona-Tarragona 1985-2004).

Clèries R, Ameijide A, Buxó M, Martínez JM, Marcos-Gragera R, Vilardell ML, Carulla M, Yasui Y, Vilardell M, Espinàs JA, Borràs JM, Galceran J, Izquierdo À.

Clin Transl Oncol. 2018 Oct;20(10):1252-1260. doi: 10.1007/s12094-018-1852-1. Epub 2018 Mar 6.

14.

[WebSurvCa: web-based estimation of death and survival probabilities in a cohort].

Clèries R, Ameijide A, Buxó M, Vilardell M, Martínez JM, Alarcón F, Cordero D, Díez-Villanueva A, Yasui Y, Marcos-Gragera R, Vilardell ML, Carulla M, Galceran J, Izquierdo Á, Moreno V, Borràs JM.

Gac Sanit. 2018 Sep - Oct;32(5):492-495. doi: 10.1016/j.gaceta.2017.10.015. Epub 2018 Jan 19. Spanish.

15.

Long-term benefits of airway clearance in bronchiectasis: a randomised placebo-controlled trial.

Muñoz G, de Gracia J, Buxó M, Alvarez A, Vendrell M.

Eur Respir J. 2018 Jan 11;51(1). pii: 1701926. doi: 10.1183/13993003.01926-2017. Print 2018 Jan.

16.

Fatty acid synthase expression and its association with clinico-histopathological features in triple-negative breast cancer.

Giró-Perafita A, Sarrats A, Pérez-Bueno F, Oliveras G, Buxó M, Brunet J, Viñas G, Miquel TP.

Oncotarget. 2017 Aug 10;8(43):74391-74405. doi: 10.18632/oncotarget.20152. eCollection 2017 Sep 26.

17.

Oncological results of the educational Rectal Cancer Project in Spain 10 years after its implementation.

Codina Cazador A, Biondo S, Espin Basany E, Enriquez-Navascues JM, Garcia-Granero E, Roig Vila JV, Buxó M; en representación de los centros participantes en el Proyecto del Cáncer de Recto de la Asociación Española de Cirujanos.

Cir Esp. 2017 Dec;95(10):577-587. doi: 10.1016/j.ciresp.2017.08.007. Epub 2017 Oct 14. English, Spanish.

PMID:
29037748
18.

Predicting the cancer burden in Catalonia between 2015 and 2025: the challenge of cancer management in the elderly.

Clèries R, Ameijide A, Marcos-Gragera R, Pareja L, Carulla M, Vilardell ML, Esteban L, Buxó M, Espinàs JA, Puigdefàbregas A, Ribes J, Izquierdo A, Galceran J, Borrás JM.

Clin Transl Oncol. 2018 May;20(5):647-657. doi: 10.1007/s12094-017-1764-5. Epub 2017 Oct 12.

19.

miRNAs in cerebrospinal fluid identify patients with MS and specifically those with lipid-specific oligoclonal IgM bands.

Quintana E, Ortega FJ, Robles-Cedeño R, Villar ML, Buxó M, Mercader JM, Alvarez-Cermeño JC, Pueyo N, Perkal H, Fernández-Real JM, Ramió-Torrentà L.

Mult Scler. 2017 Nov;23(13):1716-1726. doi: 10.1177/1352458516684213. Epub 2017 Jan 9.

PMID:
28067602
20.

Estimating long-term crude probability of death among young breast cancer patients: a Bayesian approach.

Clèries R, Buxó M, Yasui Y, Marcos-Gragera R, Martínez JM, Ameijide A, Galceran J, Borràs JM, Izquierdo À.

Tumori. 2016 Dec 1;102(6):555-561. doi: 10.5301/tj.5000545. Epub 2016 Sep 20.

PMID:
27647229
21.

Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer.

Corominas-Faja B, Vellon L, Cuyàs E, Buxó M, Martin-Castillo B, Serra D, García J, Lupu R, Menendez JA.

Histol Histopathol. 2017 Jul;32(7):687-698. doi: 10.14670/HH-11-830. Epub 2016 Oct 7.

22.

Validation of a Spanish version of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis.

Muñoz G, Buxó M, de Gracia J, Olveira C, Martinez-Garcia MA, Giron R, Polverino E, Alvarez A, Birring SS, Vendrell M.

Chron Respir Dis. 2016 May;13(2):128-36. doi: 10.1177/1479972316632005. Epub 2016 Feb 22.

23.

Contribution of changes in demography and in the risk factors to the predicted pattern of cancer mortality among Spanish women by 2022.

Clèries R, Buxó M, Martínez JM, Espinàs JA, Dyba T, Borràs JM.

Cancer Epidemiol. 2016 Feb;40:113-8. doi: 10.1016/j.canep.2015.12.002. Epub 2015 Dec 18.

24.

Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer.

Martin-Castillo B, Lopez-Bonet E, Buxó M, Dorca J, Tuca-Rodríguez F, Ruano MA, Colomer R, Menendez JA.

Oncotarget. 2015 Mar 30;6(9):7104-22.

25.

An improved axillary staging system using the OSNA assay does not modify the therapeutic management of breast cancer patients.

Ruano MA, Lopez-Bonet E, Buxó M, Tuca-Rodríguez F, Vila-Camps E, Alvarez E, Martin-Castillo B, Menendez JA.

Sci Rep. 2014 Jul 18;4:5743. doi: 10.1038/srep05743.

26.

[Bioethical reflections on ill-considered care due to an early diagnosis of Alzheimer disease].

Buxó MJ, Casado M.

Gac Sanit. 2014 Sep-Oct;28(5):426-8. doi: 10.1016/j.gaceta.2014.03.012. Epub 2014 May 19. Spanish.

27.

Cancer incidence and mortality projections up to 2020 in Catalonia by means of Bayesian models.

Ribes J, Esteban L, Clèries R, Galceran J, Marcos-Gragera R, Gispert R, Ameijide A, Vilardell ML, Borras J, Puigdefabregas A, Buxó M, Freitas A, Izquierdo A, Borras JM.

Clin Transl Oncol. 2014 Aug;16(8):714-24. doi: 10.1007/s12094-013-1140-z. Epub 2013 Dec 12.

PMID:
24338506
28.

Fatty acid synthase expression is strongly related to menopause in early-stage breast cancer patients.

Porta R, Blancafort A, Casòliva G, Casas M, Dorca J, Buxo M, Viñas G, Oliveras G, Puig T.

Menopause. 2014 Feb;21(2):188-91. doi: 10.1097/GME.0b013e31829d17dc.

PMID:
23982110
29.

Time trends of cancer incidence and mortality in Catalonia during 1993-2007.

Clèries R, Esteban L, Borràs J, Marcos-Gragera R, Freitas A, Carulla M, Buxó M, Puigdefàbregas A, Izquierdo A, Gispert R, Galceran J, Ribes J.

Clin Transl Oncol. 2014 Jan;16(1):18-28. doi: 10.1007/s12094-013-1060-y. Epub 2013 Jun 6.

PMID:
23740137
30.

Bayesian approach to predicting cancer incidence for an area without cancer registration by using cancer incidence data from nearby areas.

Clèries R, Ribes J, Buxo M, Ameijide A, Marcos-Gragera R, Galceran J, Miguel Martínez J, Yasui Y.

Stat Med. 2012 May 10;31(10):978-87. doi: 10.1002/sim.4463. Epub 2012 Jan 11.

PMID:
22237653
31.

Neuroendocrine tumors: a population-based study of incidence and survival in Girona Province, 1994-2004.

Alsina M, Marcos-Gragera R, Capdevila J, Buxó M, Ortiz RM, Barretina P, Vilardell L, Brunet J, Beltran M, Izquierdo Á.

Cancer Epidemiol. 2011 Dec;35(6):e49-54. doi: 10.1016/j.canep.2011.05.011. Epub 2011 Aug 16.

PMID:
21840785
32.

Methods for the study of employment relations and health inequalities in a global context.

Benach J, Castedo A, Solar O, Martínez JM, Vergara M, Amable M, Buxó M, Demiral Y, Muntaner C.

Int J Health Serv. 2010;40(2):209-13.

PMID:
20440965
33.

[Predictions of cancer incidence and mortality in Catalonia to 2015 by means of Bayesian models].

Ribes J, Clèries R, Buxó M, Ameijide A, Valls J, Gispert R.

Med Clin (Barc). 2008 Oct;131 Suppl 1:32-41. Spanish.

PMID:
19080813
34.

What challenges offers nanotechnology to bioethics?

Susanne C, Casado M, Buxo MJ.

Rev Derecho Genoma Hum. 2005 Jan-Jun;(22):27-45.

PMID:
16385788

Supplemental Content

Support Center